



OPEN ACCESS

EDITED AND REVIEWED BY
Gerald Nabozny,
Boehringer Ingelheim, United States

*CORRESPONDENCE

Juan D. Cañete

✉ jcanete@clinic.cat

Rubén Queiro

✉ rubenque7@yahoo.es

†These authors have contributed
equally to this work and share
first authorship

‡These authors have contributed
equally to this work and share
last authorship

RECEIVED 02 November 2023

ACCEPTED 13 November 2023

PUBLISHED 22 November 2023

CITATION

Navarro-Compán V, Puig L, Vidal S,
Ramírez J, Llamas-Velasco M,
Fernández-Carballido C, Almodóvar R,
Pinto JA, Galíndez-Aguirregoikoa E,
Zarco P, Joven B, Gratacós J, Juanola X,
Blanco R, Arias-Santiago S, Sanz JS,
Queiro R and Cañete JD (2023)
Corrigendum: The paradigm of
IL-23-independent production of
IL-17F and IL-17A and their role
in chronic inflammatory diseases.
Front. Immunol. 14:1332177.
doi: 10.3389/fimmu.2023.1332177

COPYRIGHT

© 2023 Navarro-Compán, Puig, Vidal,
Ramírez, Llamas-Velasco,
Fernández-Carballido, Almodóvar, Pinto,
Galíndez-Aguirregoikoa, Zarco, Joven,
Gratacós, Juanola, Blanco, Arias-Santiago,
Sanz, Queiro and Cañete. This is an open-
access article distributed under the terms of
the [Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases

Victoria Navarro-Compán^{1†}, Luis Puig^{2†}, Silvia Vidal³,
Julio Ramírez⁴, Mar Llamas-Velasco⁵,
Cristina Fernández-Carballido⁶, Raquel Almodóvar⁷,
José Antonio Pinto⁸, Eva Galíndez-Aguirregoikoa⁹,
Pedro Zarco⁷, Beatriz Joven¹⁰, Jordi Gratacós¹¹,
Xavier Juanola¹², Ricardo Blanco¹³,
Salvador Arias-Santiago^{14,15,16}, Jesús Sanz Sanz¹⁷,
Rubén Queiro^{18*†} and Juan D. Cañete^{4*†}

¹Department of Rheumatology, Hospital Universitario La Paz, IdiPaz, Madrid, Spain, ²Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Immunology-Inflammatory Diseases, Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain, ⁴Arthritis Unit, Department of Rheumatology, Hospital Clínic and Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁵Department of Dermatology, Hospital Universitario La Princesa, Madrid, Spain, ⁶Department of Rheumatology, Hospital Universitario San Juan de Alicante, Alicante, Spain, ⁷Department of Rheumatology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain, ⁸Department of Rheumatology, Complejo Hospitalario Universitario de A Coruña, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain, ⁹Department of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ¹⁰Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Department of Rheumatology, Medicine Department Autonomous University of Barcelona (UAB), I3PT, University Hospital Parc Taulí Sabadell, Barcelona, Spain, ¹²Department of Rheumatology, University Hospital Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain, ¹³Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain, ¹⁴Department of Dermatology, Hospital Universitario Virgen de las Nieves, Granada, Spain, ¹⁵Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain, ¹⁶Department of Dermatology, Facultad de Medicina, Universidad de Granada, Granada, Spain, ¹⁷Department of Rheumatology, Hospital Universitario Puerta del Hierro Majadahonda, Madrid, Spain, ¹⁸Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

KEYWORDS

IL-17A, IL-17F, IL-23, spondyloarthritis, Th17 cells, MAIT cells, $\gamma\delta$ T cells, psoriasis

A Corrigendum on

The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases

By Navarro-Compán V, Puig L, Vidal S, Ramírez J, Llamas-Velasco M, Fernández-Carballido C, Almodóvar R, Pinto JA, Galíndez-Aguirregoikoa E, Zarco P, Joven B, Gratacós J, Juanola X, Blanco R, Arias-Santiago S, Sanz J, Queiro R and Cañete JD (2023) *Front. Immunol.* 14:1191782. doi: 10.3389/fimmu.2023.1191782

In the published article, there was an error in **Table 1** as published. The cell corresponding to ixekizumab in HS must be yellow rather than green, since it is not approved for that indication, nor has phase 3 clinical development been published.

Also, there is no data regarding clinical studies using tildrakizumab for IBD, so the color has been changed to yellow.

The legend has been modified for clarification. The changes include the modification from “Green: Shown efficacy” to “Green: approved or shown efficacy in phase 3 clinical trials”.

The corrected Table 1 and its caption “Available therapies targeting IL-17 and IL-23 in IMIDs” appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 1 Available therapies targeting IL-17 and IL-23 in IMIDs.

Mechanism of action	Therapy	Approved indications*	PsO	PsA	axSpA	HS	IBD	Uveitis
Anti-IL-17A	Ixekizumab	Plaque psoriasis, psoriatic arthritis, axial spondylarthritis	Green	Green	Green	Yellow	Red	Red
	Secukinumab	Plaque psoriasis, psoriatic arthritis, axial spondylarthritis, juvenile idiopathic arthritis	Green	Green	Green	Green	Red	Red
Anti-IL-17RA	Brodalumab	Plaque psoriasis	Green	Yellow	Yellow	Yellow	Red	Red
Anti-IL-17A and IL-17F	Bimekizumab	Plaque psoriasis, psoriatic arthritis, and axial spondylarthritis. Phase 3 clinical development completed for hidradenitis suppurativa, EMA approval pending	Green	Green	Green	Green	Red	Yellow
Anti-IL12/23	Ustekinumab	Plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis	Green	Green	Red	Red	Green	Red
Anti-IL23p19	Guselkumab	Plaque psoriasis, psoriatic arthritis. In phase 3 clinical development for Crohn’s disease and ulcerative colitis	Green	Green	Red	Red	Green	Red
	Risankizumab	Plaque psoriasis, psoriatic arthritis, Crohn’s disease. In phase 3 clinical development for ulcerative colitis	Green	Green	Red	Red	Green	Red
	Tildrakizumab	Plaque psoriasis. In phase 3 clinical development for psoriatic arthritis	Green	Green	Red	Red	Yellow	Red

axSpA, axial spondyloarthritis; HS, hidradenitis suppurativa; IBD, inflammatory bowel disease; IL, interleukin; PsA, psoriasis arthritis; PsO, psoriasis.
 *The table only includes therapies that have been approved by the European Medicines Agency (EMA) or that have published phase 3 clinical development.
 Green: approved or shown efficacy in phase 3 clinical trials. Red: Lack of efficacy. Yellow: Insufficient or unclear evidence.